In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mitsubishi Chemical Holdings Corp.

www.mitsubishichem-hd.co.jp/english/

Latest From Mitsubishi Chemical Holdings Corp.

Top US Court Is Asked To Review Inter Partes Reviews

Standards for determining obviousness via inter partes patent reviews, as well as procedures for affirming such determinations on appeal, must be reviewed by the US Supreme Court, two originators argue in their dispute with Akorn over Durezol difluprednate eye drops.

 


Intellectual Property Legal Issues

Medicare Payment Policy For Dialysis Drugs Seeks To Promote Innovation, Restrain Costs

More new dialysis drugs would be eligible for Medicare add-on payments under proposed rule, but payment amounts would be lower.

Medicare Regulation

Biopharma Quarterly Dealmaking Statistics, Q3 2017

Third-quarter biopharma financing, which totaled $12.5 billion, was dominated by follow-on public offerings, which represented virtually half the value. Acquisition activity was headlined by a major move by Gilead in the CART market. Five alliances were signed worth over $1 billion, led by a partnership between two key players, Merck & Co. and AstraZeneca.

BioPharmaceutical Deals

In Vivo's Deals Of The Month, July 2017

In Vivo's editors pick July's most significant deals, including AZ and Merck's oncology deal, and late-stage funding for Silk Road Medical. (Free article.)

BioPharmaceutical Deals
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register